BIOMAT Database Logo BIOMAT Database Logo

Carbovir: the (-) enantiomer is a potent and selective antiviral agent against human immunodeficiency virus in vitro. 1991

J A Coates, and H J Inggall, and B A Pearson, and C R Penn, and R Storer, and C Williamson, and J M Cameron
Department of Virology, Glaxo Group Research Limited, Greenford, U.K.

In this paper we describe the in vitro antiviral activity of the (-) enantiomer of carbocyclic 2',3'-deoxydidehydroguanosine, (-) carbovir, a nucleoside analogue that has selective and potent anti-HIV activity in a series of lymphocyte culture systems. The cellular cytotoxicity of this compound has also been evaluated in a number of systems and compared to the saturated dideoxynucleoside analogues AZT and ddC.

UI MeSH Term Description Entries
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014758 Viral Core Proteins Proteins found mainly in icosahedral DNA and RNA viruses. They consist of proteins directly associated with the nucleic acid inside the NUCLEOCAPSID. Core Proteins, Viral,Major Core Protein,Major Core Proteins, Viral,Adenovirus Core Protein VII,Core Protein V,Core Protein lambda 2,Influenza Virus Core Proteins,Major Core Protein lambda 1,Major Core Protein lambda-1,Major Core Protein sigma 2,Major Core Protein sigma-2,OVP 19,Oncornaviral Protein P19,P30 Core Proteins,Viral Protein P19,Virus Core Proteins,Core Protein, Major,Core Proteins, P30,Core Proteins, Virus,Protein P19, Oncornaviral,Protein P19, Viral,Protein, Major Core,Proteins, P30 Core,Proteins, Viral Core,Proteins, Virus Core
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015224 Dideoxynucleosides Nucleosides that have two hydroxy groups removed from the sugar moiety. The majority of these compounds have broad-spectrum antiretroviral activity due to their action as antimetabolites. The nucleosides are phosphorylated intracellularly to their 5'-triphosphates and act as chain-terminating inhibitors of viral reverse transcription. 2',3'-Dideoxynucleosides,Dideoxyribonucleosides,ddNus,2',3' Dideoxynucleosides
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015726 Giant Cells Multinucleated masses produced by the fusion of many cells; often associated with viral infections. In AIDS, they are induced when the envelope glycoprotein of the HIV virus binds to the CD4 antigen of uninfected neighboring T4 cells. The resulting syncytium leads to cell death and thus may account for the cytopathic effect of the virus. Giant Cells, Multinucleated,Multinucleated Giant Cells,Polykaryocytes,Syncytium,Syncytia,Cell, Giant,Cell, Multinucleated Giant,Cells, Giant,Cells, Multinucleated Giant,Giant Cell,Giant Cell, Multinucleated,Multinucleated Giant Cell,Polykaryocyte

Related Publications

J A Coates, and H J Inggall, and B A Pearson, and C R Penn, and R Storer, and C Williamson, and J M Cameron
Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro.
October 1988, Biochemical and biophysical research communications,
J A Coates, and H J Inggall, and B A Pearson, and C R Penn, and R Storer, and C Williamson, and J M Cameron
Resolution of racemic carbovir and selective inhibition of human immunodeficiency virus by the (-) enantiomer.
May 1990, Biochemical and biophysical research communications,
J A Coates, and H J Inggall, and B A Pearson, and C R Penn, and R Storer, and C Williamson, and J M Cameron
Activities of (-)-carbovir and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro.
June 1990, Antimicrobial agents and chemotherapy,
J A Coates, and H J Inggall, and B A Pearson, and C R Penn, and R Storer, and C Williamson, and J M Cameron
Liquid chromatographic assay of carbovir, a carbocyclic nucleoside active against human immunodeficiency virus.
April 1989, Journal of chromatography,
J A Coates, and H J Inggall, and B A Pearson, and C R Penn, and R Storer, and C Williamson, and J M Cameron
Development of new potent and selective agents against HIV (human immunodeficiency virus).
January 1991, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie,
J A Coates, and H J Inggall, and B A Pearson, and C R Penn, and R Storer, and C Williamson, and J M Cameron
Pharmacokinetics and bioavailability of carbovir, a carbocyclic nucleoside active against human immunodeficiency virus, in rats.
February 1989, Antimicrobial agents and chemotherapy,
J A Coates, and H J Inggall, and B A Pearson, and C R Penn, and R Storer, and C Williamson, and J M Cameron
Selective antiviral activity of synthetic soluble L-tyrosine and L-dopa melanins against human immunodeficiency virus in vitro.
January 1991, Antiviral research,
J A Coates, and H J Inggall, and B A Pearson, and C R Penn, and R Storer, and C Williamson, and J M Cameron
Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro.
August 1995, The Journal of infectious diseases,
J A Coates, and H J Inggall, and B A Pearson, and C R Penn, and R Storer, and C Williamson, and J M Cameron
Metabolism of 4'-azidothymidine. A compound with potent and selective activity against the human immunodeficiency virus.
January 1992, The Journal of biological chemistry,
J A Coates, and H J Inggall, and B A Pearson, and C R Penn, and R Storer, and C Williamson, and J M Cameron
In vitro antiviral activity of a peptide-nucleic acid solution against the human immunodeficiency virus and influenza A virus.
October 1991, Journal of the Royal Society of Health,
Copied contents to your clipboard!